Suppr超能文献

相似文献

1
Turning severe into moderate haemophilia by prophylaxis: are we reaching our goal?
Blood Transfus. 2013 Jul;11(3):364-9. doi: 10.2450/2012.0092-12. Epub 2012 Nov 6.
2
Outcome in moderate haemophilia.
Blood Transfus. 2014 Jan;12 Suppl 1(Suppl 1):s330-6. doi: 10.2450/2012.0091-12. Epub 2012 Nov 20.
3
Prophylaxis for severe haemophilia: clinical and economical issues.
Haemophilia. 2003 Jul;9(4):376-81. doi: 10.1046/j.1365-2516.2003.00764.x.
4
Clinical outcome of moderate haemophilia compared with severe and mild haemophilia.
Haemophilia. 2009 Jan;15(1):83-90. doi: 10.1111/j.1365-2516.2008.01837.x. Epub 2008 Aug 16.
5
Can long-term prophylaxis for severe haemophilia be stopped in adulthood? Results from Denmark and the Netherlands.
Br J Haematol. 2005 Jul;130(1):107-12. doi: 10.1111/j.1365-2141.2005.05546.x.
6
Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B.
Cochrane Database Syst Rev. 2024 Feb 27;2(2):CD014544. doi: 10.1002/14651858.CD014544.pub2.
7
Joint health and treatment modalities in Nordic patients with moderate haemophilia A and B - The MoHem study.
Haemophilia. 2020 Sep;26(5):891-897. doi: 10.1111/hae.14114. Epub 2020 Jul 27.
8
When should prophylactic treatment in patients with haemophilia A and B start?--The German experience.
Haemophilia. 1998 Jul;4(4):413-7. doi: 10.1046/j.1365-2516.1998.440413.x.
9
Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s.
Blood. 2013 Aug 15;122(7):1129-36. doi: 10.1182/blood-2012-12-470898. Epub 2013 Jun 18.
10
Discontinuing early prophylaxis in severe haemophilia leads to deterioration of joint status despite low bleeding rates.
Thromb Haemost. 2016 May 2;115(5):931-8. doi: 10.1160/TH15-08-0637. Epub 2016 Jan 21.

引用本文的文献

2
Joint health status in people with moderate hemophilia A: a cross-sectional multicenter study.
Res Pract Thromb Haemost. 2025 Mar 19;9(2):102737. doi: 10.1016/j.rpth.2025.102737. eCollection 2025 Feb.
4
Asymptomatic Joint Bleeding and Joint Health in Hemophilia: A Review of Variables, Methods, and Biomarkers.
J Blood Med. 2021 Apr 1;12:209-220. doi: 10.2147/JBM.S304597. eCollection 2021.
5
Patient Preferences to Assess Value IN Gene Therapies: Protocol Development for the PAVING Study in Hemophilia.
Front Med (Lausanne). 2021 Mar 9;8:595797. doi: 10.3389/fmed.2021.595797. eCollection 2021.
7
MRI predicts 5-year joint bleeding and development of arthropathy on radiographs in hemophilia.
Blood Adv. 2020 Jan 14;4(1):113-121. doi: 10.1182/bloodadvances.2019001238.

本文引用的文献

1
Prevention of joint damage in hemophilic children with early prophylaxis.
Orthopade. 1999 Apr;28(4):341-346. doi: 10.1007/PL00003616.
2
Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia.
Haemophilia. 2011 Jan;17(1):2-10. doi: 10.1111/j.1365-2516.2010.02370.x. Epub 2010 Aug 22.
3
Prophylaxis in the haemophilia population.
Haemophilia. 2010 Jul;16 Suppl 5:181-8. doi: 10.1111/j.1365-2516.2010.02318.x.
5
Participation and risk-taking behaviour in sports in children with haemophilia.
Haemophilia. 2009 May;15(3):686-94. doi: 10.1111/j.1365-2516.2009.02006.x.
6
Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A.
J Thromb Haemost. 2009 Mar;7(3):413-20. doi: 10.1111/j.1538-7836.2008.03270.x. Epub 2008 Dec 20.
7
Cryoprecipitate in the treatment of hemophilia.
Calif Med. 1970 Aug;113(2):66-7.
8
A survey of adherence to haemophilia therapy in six European countries: results and recommendations.
Haemophilia. 2008 Sep;14(5):931-8. doi: 10.1111/j.1365-2516.2008.01843.x. Epub 2008 Aug 4.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验